The DOI matches its Crossref record; 190 of the 191 references it cites were found in a registry or an index; 67 of the 105 sources its claims cite were checked for support.
Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review
Open accessAbstract
Regulatory T cells (Tregs) expressing the transcription factor FoxP3 are essential for maintaining immunological balance and are a significant component of the immunosuppressive tumor microenvironment (TME). Single-cell RNA sequencing (ScRNA-seq) technology has shown that Tregs exhibit significant plasticity and functional diversity in various tumors within the TME. This results in Tregs playing a dual role in the TME, which is not always centered around supporting tumor progression as typically believed. Abundant data confirms the anti-tumor activities of Tregs and their correlation with enhanced patient prognosis in specific types of malignancies. In this review, we summarize the potential anti-tumor actions of Tregs, including suppressing tumor-promoting inflammatory responses and boosting anti-tumor immunity. In addition, this study outlines the spatial and temporal variations in Tregs function to emphasize that their predictive significance in malignancies may change. It is essential to comprehend the functional diversity and potential anti-tumor effects of Tregs to improve tumor therapy strategies.
Overview
CoChat Summary
## TL;DR
This review argues that regulatory T cells (Tregs) in the tumor microenvironment are not uniformly pro-tumor; instead, some Treg subpopulations can support anti-tumor immunity or suppress tumor-promoting inflammation. It also emphasizes that Tregs’ prognostic and therapeutic significance varies by tumor type, location, and stage.
## Key findings
- The review summarizes evidence that Tregs can have anti-tumor effects through two main routes: boosting anti-tumor immunity and suppressing tumor-promoting inflammation.
- Single-cell RNA sequencing is highlighted as showing substantial Treg plasticity and heterogeneity; the paper describes stable, unstable, fragile, Th1-like, Th17-like, and other Treg subgroups.
- In several cancers, higher Treg infiltration is linked with better outcomes: the paper cites colorectal cancer (CRC), head and neck squamous cell carcinoma (HNSCC), and gastric cancer (GC), and reports a 52% greater chance of survival in HER2+/ER− breast cancer patients with higher CD8+ T cells and increased FoxP3+ Treg infiltration.
- Prognostic effects vary by context: in pancreatic cancer, one cited study found higher Tregs associated with shorter OS/DFS, while another found significant Treg infiltration extended survival; in gastric cancer, early-stage (I–II) high FoxP3+ Treg infiltration was associated with better 5-year survival, whereas stage III–IV was associated with worse prognosis.
## Methods
- Narrative review of published studies on Tregs in the tumor microenvironment, with emphasis on single-cell RNA sequencing, spatial heterogeneity, and functional subgrouping of Tregs.
- The paper synthesizes findings across multiple tumor types and cites both clinical studies and preclinical models (including mouse models) to support proposed mechanisms.
- Main analysis is qualitative and integrative: it groups reported Treg effects into anti-tumor immunity and suppression of tumor-promoting inflammation, then discusses prognostic heterogeneity by tumor type, tumor region, and tumor stage.
## Limitations
- The paper states that many of the studies analyzed focused solely on clinical data, and it calls for more work on the biological basis of Tregs in cancer.
- It states that few studies have examined the correlation between tumor stage and Tregs function, so the stage-specific relationship remains insufficiently understood.
- Evident from the text: this is a review, so its conclusions depend on heterogeneous prior studies with differing markers, tumor types, and definitions of Tregs; the paper itself notes that current markers are often insufficient to distinguish functional subgroups accurately.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Three subgroups can be identified based on phenotype and function of Tregs. Stable Tregs: express FoxP3, have immunosuppressive function; Unstable Tregs: express low or no FoxP3 that secrete IFN-γ and can promote anti-tumor immunity; Fragile Tregs: express FoxP3 while secreting IFN-γ, and have anti-tumor activity [30]](/paper-figures/fc7c7877479a4000bd37612d0eea7ff2/potential-anti-tumor-effects-of-regulatory-t-cells-in-the-tumor-microenvironment-figure-1.jpg)



Verification
Claims the paper makes
49 Valid · 7 Not valid · 29 Not checked · 24 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“TAMs, which are a significant element of TME, frequently shows a positive correlation with the depth of tumor infiltration and clinical staging [118].”
§ Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review > Potential anti-tumor effects > Regulatory role of stable Tregs in tumor-promoting inflammation
What the sources say
- Disputedcites [118] Xue T, Yan K, Cai Y, Sun J, Chen Z, Chen X, Wu W. Prognostic significance of CD163+ tumor-associated macrophages in colorectal cancer. World J Surg Oncol. 2021;19:186. https://doi.org/10.1186/s12957-021-02299-y. sourceExperimental — accuracy not yet measured
In Results, under “Association between CD163+ TAM infiltration and clinical characteristics” (page unavailable), the authors report no significant difference in TNM stage between the high- and low-CD163+ TAM groups; Table 1 gives P = 0.599. The cited paper therefore does not support the claimed positive correlation with clinical staging. It does not report an analysis of tumor-infiltration depth. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Increased presence of Tregs is linked to decreased patient survival in several types of malignancies [5–7].”
§ Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review > Background
What the sources say
- Partly supportedcites [5] Sayour EJ, McLendon P, McLendon R, De Leon G, Reynolds R, Kresak J, Sampson JH, Mitchell DA. Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother. 2015;64:419–27. https://doi.org/10.1007/s00262-014-1651-7. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) links lower effector-T-cell-to-FoxP3+ ratios with reduced survival in primary glioblastoma, but says FoxP3 expression alone was not associated with outcomes. The Introduction discusses other malignancies, yet does not establish that increased Treg presence predicts decreased survival across several cancer types. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [6] Peng J, Yang S, Ng CSH, Chen GG. The role of FOXP3 in non-small cell lung cancer and its therapeutic potentials. Pharmacol Ther. 2023;241: 108333. https://doi.org/10.1016/j.pharmthera.2022.108333. source
- Partly supportedcites [7] Kos K, de Visser KE. The multifaceted role of regulatory T cells in breast cancer. Annu Rev Cancer Biol. 2021;5:291–310. https://doi.org/10.1146/annurev-cancerbio-042920-104912. sourceExperimental — accuracy not yet measured
The “Prognostic Value of Tregs in Breast Cancer” section reports that high FOXP3-positive T-cell infiltration correlates with poor survival in HR-positive breast cancer. It does not establish decreased survival across several malignancy types; it also reports a favorable prognosis association in HR-negative and triple-negative breast cancer. Page numbers were not available in our copy. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, IL-2 interacts to IL-2R on Tregs’ cell surface, maintaining FoxP3 expression via activating downstream STAT5 [38].”
§ Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review > Potential anti-tumor effects > Tregs promote anti-tumor immune responses
What the sources say
- Partly supportedcites [38] Permanyer M, Bošnjak B, Glage S, Friedrichsen M, Floess S, Huehn J, Patzer GE, Odak I, Eckert N, Zargari R, Ospina-Quintero L, Georgiev H, Förster R. Efficient IL-2R signaling differentially affects the stability, function, and composition of the regulatory T-cell pool. Cell Mol Immunol. 2021;18:398–414. https://doi.org/10.1038/s41423-020-00599-z. sourceExperimental — accuracy not yet measured
The Introduction says IL-2 binds IL-2R, and the Results report IL-2-induced STAT5 phosphorylation in Tregs. The Discussion finds that efficient IL-2R signaling is required for sustained Foxp3 expression under inflammatory conditions. It does not establish that STAT5 activation is the mechanism maintaining Foxp3 expression, and it notes that Foxp3 expression persisted, though at a lower level, under steady-state conditions with impaired signaling. No page numbers are available in our copy. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Several elements, including Nrp1, Foxo1, and Eos, are essential in maintaining the stability of Tregs [45].”
§ Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review > Potential anti-tumor effects > Tregs promote anti-tumor immune responses
What the sources say
- Supportedcites [45] Overacre AE, Vignali DAA. Treg stability: to be or not to be. Curr Opin Immunol. 2016;39:39–43. https://doi.org/10.1016/j.coi.2015.12.009. source
The Conclusions section says that Foxo1/3a, Eos, and the Nrp1:Sema4a axis contribute to and are required for maintaining a stable Treg phenotype. The section on how Treg stability is maintained discusses each factor's role. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, the type I IFN/IFNAR1 pathway can induce the transformation of Tregs to fragile Tregs [42].”
§ Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review > Potential anti-tumor effects > Tregs promote anti-tumor immune responses
What the sources say
- Supportedcites [42] Zhang H, Tomar VS, Li J, Basavaraja R, Yan F, Gui J, McBrearty N, Costich TL, Beiting DP, Blanco MA, Conejo-Garcia JR, Saggu G, Berger A, Nefedova Y, Gabrilovich DI, Fuchs SY. Protection of regulatory T cells from fragility and inactivation in the tumor microenvironment. Cancer Immunol Res. 2022;10:1490–505. https://doi.org/10.1158/2326-6066.CIR-22-0295. source
In Results, under “Reactivating IFNAR1 in Treg cells induces their fragility and suppresses tumor growth” (page not provided), the paper reports that activating the type I interferon pathway can induce Treg fragility in an IFNAR1-dependent manner. The Discussion also describes IFN1-induced changes that contribute to the fragility phenotype. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
55 more claims · 23 with their cited sources checked
Create a free account to see all 109 claims and to verify the 4 references still open.
- It may state two separate claims as one. 47
- Probably not a substantial claim. 2
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“Additionally, they induce tumor angiogenesis and chemoresistance, promoting the proliferation and invasion of tumor cells [81].”
BackgroundType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 1×
“In CRC, Tregs situated in the tumor mesenchyme result in a better prognosis, whereas Tregs residing in the tumor nests and infiltrating margins are linked to unfavorable clinical outcomes [142, 143].”
BackgroundElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 1×
“Tumors can be classified into “immune desert”, “immune exclusion”, and “inflammatory” categories based on the number of infiltrated CD8 + T lymphocytes [138, 139].”
BackgroundMatrix Metalloproteinases: Regulators of the Tumor Microenvironment
Kessenbrock, K., Plaks, V., & Werb, Z. (2010) · Cell · doi:10.1016/j.cell.2010.03.015 · Cited by 5,151 · cited 1×
“MMPs release and activate VEGF ligands, which are crucial for tumor metastasis [108].”
BackgroundThe biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366 · cited 2×
“In addition, the depletion of Tregs results in the upregulation of the expression of immunosuppressive genes, including arginase1 and CD274 (PD-L1) [132].”
BackgroundThe evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
de Visser, K. E., & Joyce, J. A. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.016 · Cited by 4,059
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792 · cited 1×
“Inflammatory cells and cytokines in the TME can enhance tumor angiogenesis, facilitating tumor growth and spread [17].”
BackgroundSelf-citationAlternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745 · cited 1×
“Th2 cells alternatively activates M2-TAMs through secretion of IL-4 and IL-13 cytokines [96].”
BackgroundAnderson, N. M., & Simon, M. C. (2020) · Current Biology · doi:10.1016/j.cub.2020.06.081 · Cited by 2,718
CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells
Liu, W., Putnam, A. L., Xu-yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. A., Kapranov, P., Gingeras, T. R., de St. Groth, B. F., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20060772 · Cited by 2,606
Cited by
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Regulatory T cells in immune checkpoint blockade antitumor therapy
Zhang, A., Fan, T., Liu, Y., Yu, G., Li, C., & Jiang, Z. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02156-y · Cited by 188
“In colorectal cancer, Tregs in the tumor mesenchyme contribute to a better prognosis compared to those in the tumor nests and swelling margins [200].”
BackgroundCD4+ T cells in antitumor immunity
Montauti, E. I., Oh, D. Y., & Fong, L. H. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.07.009 · Cited by 182
Thuya, W. L., Cao, Y., Ho, P. C., Wong, A. L., Wang, L., Zhou, J., Nicot, C., & Goh, B. C. (2025) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2025.01.003 · Cited by 162
Lin, A., Xiong, M., Jiang, A., Huang, L., Wong, H. Z. H., Feng, S., Zhang, C., Yu, H., Chen, L., Chi, H., et al. (2025) · iMeta · doi:10.1002/imt2.70070 · Cited by 107
Self-citation
Metadata
- Authors
- Li, Y., Zhang, C., Jiang, A., Lin, A., Liu, Z., Cheng, X., Wang, W., Cheng, Q., Zhang, J., Wei, T., & Luo, P.
- Affiliations
- Zhujiang Hospital (CN)
- Xi'an Jiaotong University (CN)
- Second Military Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Harbin Medical University (CN)
- Central South University (CN)
- Corresponding author
- Cheng, Quan
- Zhang, Jian
- Wei, Ting
- Luo, Peng
- ORCID
- Luo, Peng
- Venue
- Journal of Translational Medicine
- Published
- 2024-03-20
- Volume
- 22
- Issue
- 1
- Pages
- 293-293
- ISSN
- 1479-5876 (ISSN-L)
- PMC
- PMC10953261
- OpenAlex
- W4393011526
- Cited by
- 105
- References
- 191
- Citations by year
- 2026: 34 · 2025: 55 · 2024: 15
- FWCI
- 15.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Translational Medicine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Natural Science Foundation of Guangdong Province (2018A030313846, 2021A1515012593)
- Science and Technology Planning Project of Guangdong Province (2019A030317020)
- the National Natural Science Foundation of China (81802257, 81871859, 81772457, 82172750, 82172811, 82260546)
- Guangdong Basic and Applied Basic Research Foundation (2022A1515111212)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Keywords
- regulatory T cells, Foxp3, tumor microenvironment, antitumor immunity, immunosuppression, Treg plasticity, Treg heterogeneity, tumor inflammation
- MeSH terms
- Humans, Immunotherapy, Neoplasms, T-Lymphocytes, Regulatory
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review. https://app.cochat.ai/papers/10.1186/s12967-024-05104-y
- The paper
- Li, Y., Zhang, C., Jiang, A., Lin, A., Liu, Z., Cheng, X., Wang, W., Cheng, Q., Zhang, J., Wei, T., & Luo, P. (2024). Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review. Journal of Translational Medicine. https://doi.org/10.1186/s12967-024-05104-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.